ArticleThe British journal of surgery2022
Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer.
Article in The British journal of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- ASO Author Reflections: From Recurrence Patterns to Risk-Adapted Care in Esophagogastric Junction Adenocarcinoma.Annals of surgical oncology · 2026Article
- Patterns of Recurrence in Adenocarcinoma of the Esophagogastric Junction: ERECS Trial Post Hoc Analysis.Annals of surgical oncology · 2026Article
- Patterns, Timing, and Survival of Recurrence After Surgery for Esophageal and Junctional Adenocarcinoma in the European Multicentre ENSURE Study.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Patterns, Timing, and Survival of Recurrence after Surgery for Esophageal and Junctional Adenocarcinoma.Annals of surgical oncology · 2026Article
- Prognostic value of [BMC medical imaging · 2026Article
- Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic gastroesophageal adenocarcinoma.British journal of cancer · 2026Article
- Characteristics, treatment, and outcome of recurrent gastro-oesophageal adeno-carcinoma after perioperative chemotherapy and radical resection.Acta oncologica (Stockholm, Sweden) · 2026Article
- A cost-effectiveness analysis of the effect of hospital variation in the probability of providing treatment with curative intent in potentially curable esophageal and gastric cancer patients.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma.ESMO gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPatients with cancer of the oesophagus or gastro-oesophageal junction have a high risk of recurrence after treatment with curative intent. The aim of this study was to analyse the site of recurrence, treatment, and survival in patients with recurrent disease.
methodsPatients with non-metastatic oesophageal or junctional carcinoma treated with curative intent between January 2015 and December 2016 were selected from the Netherlands Cancer Registry. Data on recurrence were collected in the second half of 2019. Overall survival (OS) was assessed by Kaplan-Meier methods.
resultsIn total, 862 of 1909 patients (45.2 per cent) for whom information on follow-up was available had disease recurrence, and 858 patients were included. Some 161 of 858 patients (18.8 per cent) had locoregional recurrence only, 415 (48.4 per cent) had distant recurrence only, and 282 (32.9 per cent) had combined locoregional and distant recurrence. In all, 518 of 858 patients (60.4 per cent) received best supportive care only and 315 (39.6 per cent) underwent tumour-directed therapy. Patients with locoregional recurrence alone more often received chemoradiotherapy than those with distant or combined locoregional and distant recurrence (19.3 per cent versus 0.7 and 2.8 per cent), and less often received systemic therapy (11.2 per cent versus 30.1 and 35.8 per cent). Median OS was 7.6, 4.2, and 3.3 months for patients with locoregional, distant, and combined locoregional and distant recurrence respectively (P < 0.001).
conclusionDisease recurred after curative treatment in 45.2 per cent of patients. Locoregional recurrence developed in only 18.8 per cent. The vast majority of patients presented with distant or combined locoregional and distant recurrence, and received best supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.